These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 22976254)

  • 1. Is a lower dose of cyclosporine required among Iranian kidney transplant recipients?
    Nourbala MH; Heidari F
    Iran J Kidney Dis; 2012 Sep; 6(5):327-9. PubMed ID: 22976254
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal blood concentration of cyclosporine among Iranian kidney transplant recipients.
    Rostami Z; Einollahi B; Morshedi J; Teimoori M
    Iran J Kidney Dis; 2012 Sep; 6(5):373-9. PubMed ID: 22976264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine trough level or 2-hour postdose level monitoring among kidney transplant recipients: Iranian practice.
    Einollahi B; Rostami Z; Teimoori M
    Iran J Kidney Dis; 2012 Sep; 6(5):389-90. PubMed ID: 22976267
    [No Abstract]   [Full Text] [Related]  

  • 4. Is the lower cyclosporine concentration at 2 hours after dosing safe in kidney transplant recipients?
    Einollahi B; Rostami Z; Kalantar E; Lessan-Pezeshki M; Pourfarziani V; Nemati E
    Transplant Proc; 2011 Mar; 43(2):488-90. PubMed ID: 21440741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of seasonal changes on the cyclosporine A blood levels in renal transplant recipients during childhood.
    Kavukçu S; Soylu A; Türkmen M; Bora S; Güven H; Gülay H
    Nephron; 1999; 81(3):366-7. PubMed ID: 10050102
    [No Abstract]   [Full Text] [Related]  

  • 6. Do early cyclosporine levels affect the incidence of acute rejection in renal transplant recipients?
    Johnson EM; Canafax DM; Gillingham K; Schmidt W; Pandian K; Najarian JS; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):879. PubMed ID: 8623444
    [No Abstract]   [Full Text] [Related]  

  • 7. Is C0 better than C2 as a determinant of rejection in renal transplant recipients?
    Midtvedt K
    Kidney Int; 2004 Aug; 66(2):869. PubMed ID: 15253751
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclosporine trough levels in renal graft recipients.
    Jauhari H; Wadhawan S; Yashpal ; Kumar A
    J Indian Med Assoc; 1999 Nov; 97(11):476-7. PubMed ID: 10638120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients.
    Thakur V; Kumar R; Dhawan IK
    Ann Clin Biochem; 2002 Jan; 39(Pt 1):70-2. PubMed ID: 11853195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of kidney functions and cyclosporine levels in renal transplant patients on Panimum Bioral in post transplant period.
    Sharma DR; Singh S
    J Indian Med Assoc; 1999 May; 97(5):204-5. PubMed ID: 10652891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoral--a new microemulsion formula of cyclosporine A: interpatient pharmacokinetic variability in renal transplant recipients.
    Klauser R; Irschik H; Kletzmayr J; Sturm I; Brunner W; Woloszczuk W; Kovarik J
    Transplant Proc; 1995 Dec; 27(6):3427-9. PubMed ID: 8540034
    [No Abstract]   [Full Text] [Related]  

  • 13. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cyclosporine blood levels after nisoldipine administration in a renal transplant recipient.
    Fourtounas C; Kopelias I; Kiriaki D; Agroyannis B
    Transpl Int; 2002 Nov; 15(11):586-8. PubMed ID: 12461666
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cyclosporine dose monitorization in renal transplantation C2 vs C0].
    Marcén R; Villafruela JJ
    Nefrologia; 2005; 25(2):106-12. PubMed ID: 15912646
    [No Abstract]   [Full Text] [Related]  

  • 16. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
    Trotter JF; Stolpman N; Wachs M; Bak T; Kugelmas M; Kam I; Everson GT
    Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C2 monitoring: a reliable tool in pediatric renal transplant recipients.
    Dello Strologo L; Pontesilli C; Rizzoni G; Tozzi AE
    Transplantation; 2003 Jul; 76(2):444-5. PubMed ID: 12883218
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of hepatitis C virus infection on cyclosporine trough levels in renal transplant patients.
    Tuncer M; Süleymanlar G; Ersoy FF; Yakupoğlu G
    Transplant Proc; 2000 May; 32(3):569-71. PubMed ID: 10812116
    [No Abstract]   [Full Text] [Related]  

  • 19. [Serum cyclosporine levels in patients after kidney transplantation].
    Karamehić J; Ascerić M; Tulumović T; Uzeirbegović M; Hadzibegić N
    Med Arh; 1998; 52(3):131-2. PubMed ID: 9863315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy.
    Hesselink DA; van Dam T; Metselaar HJ; Balk AH; Mathôt RA; Smak Gregoor PJ; Weimar W; van Gelder T
    Transpl Int; 2004 Oct; 17(9):495-504. PubMed ID: 15338117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.